Is it Time for a Curcumin-Based Mesothelioma Treatment?
Yet another scientific study appears to confirm the power of the spice-derived compound curcumin as a weapon against malignant pleural mesothelioma. The Chinese researchers who conducted the latest study say the substance has the potential to be the basis of a whole new way of treating this aggressive asbestos cancer. This team tested curcumin on a line of mouse mesothelioma cells, both in the lab and in live animals, and published their promising results in the prestigious International Journal of Oncology. Curcumin’s Impact on Mesothelioma Cells Curumin is a primary chemical in turmeric, responsible for the root’s spicy flavor and characteristic yellow hue. If turmeric does, in fact, help fight cancer, as so many health food stores and supplement makers … Continue reading Is it Time for a Curcumin-Based Mesothelioma Treatment?
Milk for Mesothelioma? Proteins in Cow’s Milk May Kill Mesothelioma Cells
There is new evidence that substances in cow’s milk may trigger a physiological process that leads to the death of chemotherapy-resistant mesothelioma cells. The substances are known as BAMLET and BLAGLET and they consist of either alpha- or beta-lactalbumin from cow’s milk and a lipid called oleic acid. The two protein-lipid complexes have been shown to have cytotoxic effects on eight other types of cancer. Now, researchers in Sydney, Australia have found that the same may be true for malignant mesothelioma, one of the hardest cancers to treat. BAMLET and BLAGLET Explained β-Lactoglobulin is the primary whey protein in the milk of cow’s and sheep (though not humans). α-Lactalbumin is the protein that regulates the production of lactose in … Continue reading Milk for Mesothelioma? Proteins in Cow’s Milk May Kill Mesothelioma Cells
Study Predicts New Mesothelioma Therapies on the Horizon
A new article published by a pair of UK scientists predicts a brighter future for mesothelioma patients thanks to a growing understanding of the disease and how to treat it. Malignant mesothelioma is the cancer most closely associated with asbestos. Although only a small percentage of asbestos-exposed people go on to develop mesothelioma, those who do face a grim prognosis. Doctors learned early on that standard cancer treatments rarely work for patients with mesothelioma. But Anna Bibby and Nick Maskell with Bristol Medical School and the North Bristol Lung Centre say the large amount of high-quality mesothelioma research conducted in the last decade has moved medicine closer to finding a cure for this intractable cancer. Important Mesothelioma Research Findings In … Continue reading Study Predicts New Mesothelioma Therapies on the Horizon
Opdivo for Malignant Mesothelioma: Could a Lower Dose Work?
There is new evidence that low doses of the drug Opdivo (nivolumab) may extend lung cancer survival as well as the standard dose—at a much lower cost. The news may have implications for people with the lung-related asbestos cancer, malignant mesothelioma, who are also sometimes treated with Opdivo. Pleural mesothelioma is a hard-to-treat cancer that grows on the lining around the lungs and causes many of the same symptoms as lung cancer. Some evidence has suggested that Opdivo, an immunotherapy drug already approved for the treatment of recurrent lung cancer, may soon become the first drug approved for recurrent mesothelioma, too. Now, a newly-published Korean study finds that patients may not need as much of the drug as originally thought … Continue reading Opdivo for Malignant Mesothelioma: Could a Lower Dose Work?
Compound Makes Mesothelioma Tumors More Susceptible to Chemo
Swiss cancer researchers may have found a way to get around malignant mesothelioma’s notorious resistance to chemotherapy with an investigational metal-based compound called RAPTA-T. Malignant pleural mesothelioma is an incurable and highly aggressive cancer. One of the reasons it is so deadly is that it rarely responds to standard cancer treatments. Even the treatment combination that is considered the standard of care for pleural mesothelioma—pemetrexed (Alimta) and cisplatin—is only effective in about 4 out of 10 patients. But scientists with Centre Hospitalier Universitaire Vaudois and the Swiss Federal Institute of Technology in Lausanne, Switzerland have discovered a counterintuitive way to ramp up the cancer-killing power of mesothelioma chemotherapy. Creating a “Healthier” Tumor The element on which the RAPTA-T compound is … Continue reading Compound Makes Mesothelioma Tumors More Susceptible to Chemo
Experimental Mesothelioma Drugs and the New Right-to-Try Law
Legislation signed this week by President Trump could pave the way for mesothelioma patients to access promising experimental treatments—even years before they are approved by the FDA. But not everyone thinks it is a good idea. The “Right to Try” legislation gives patients with terminal illnesses like malignant mesothelioma the right to receive new treatments they would not normally be able to get because they haven’t gone through the FDA’s three-phase testing requirement. Controversy Over New Legislation Although the legislation could make it easier for some patients to access potentially life-saving mesothelioma treatments, it is also not without controversy. Some argue it could even be dangerous. Typically, the FDA requires that all proposed mesothelioma therapies go through three-phases of studies … Continue reading Experimental Mesothelioma Drugs and the New Right-to-Try Law
Immunotherapy Combo Shows Early Efficacy for Malignant Mesothelioma
AstraZeneca’s immunotherapy drug tremelimumab may still have a chance as a novel mesothelioma treatment, even though an international clinical trial completed last year found that it did not extend mesothelioma survival. In a new study published in The Lancet Respiratory Medicine, Italian researchers report that combining the monoclonal antibody with another drug called durvalumab “appeared active” as a second-line mesothelioma treatment with “a good safety profile”. Tremelimumab’s Rocky Start as a Mesothelioma Treatment Hopes were initially high for tremelimumab, a monoclonal antibody that works by binding to the protein CTLA-4 on the surface of white blood cells and preventing it from inhibiting the cells’ cancer-fighting power. The US even granted tremelimumab “orphan drug” status in 2015, a designation designed to … Continue reading Immunotherapy Combo Shows Early Efficacy for Malignant Mesothelioma
Tea Leaf Cancer Treatment May Have Implications for Mesothelioma Patients
A new type of nanoparticle derived from green tea leaves has been shown to kill lung cancer cells and may one day do the same for pleural mesothelioma. Scientists at Swansea University in Wales in collaboration with researchers at Bharathiar University in India discovered the power of the tea-based nanoparticles—called quantum dots—when attempting to create a less expensive tool for lung cancer imaging. “The main reason we started looking at tea leaves is that chemically synthesised quantum dots cost between £250 and £500 per microgram,” lead researcher Dr. Sudhagar Pitchaimuthu told the BBC. “Whereas organically-derived ones can be manufactured for £10 per microgram, and at the same time they don’t poison healthy cells surrounding the cancer.” Fluorescent Cancer Fighters Nanoparticles … Continue reading Tea Leaf Cancer Treatment May Have Implications for Mesothelioma Patients
Mesothelioma Patients Recruited to Test Promising New Combo Drug
Patients with malignant mesothelioma who have not gotten better after chemotherapy are being invited to enroll in a clinical trial of a combination drug that could be the future of mesothelioma treatment. The drug is called SEL-403. Developed by Selecta Biosciences, the drug seeks to get around the problem of the body producing antibodies that decrease the effectiveness of certain mesothelioma drugs. What is SLE-403 and How Could it Improve Mesothelioma Treatment? SEL-403 is a combination of two agents, The first is LMB-100, an immunotoxin that targets the protein mesothelin, which is overproduced by most mesothelioma tumors as well as by several other types of cancer cells. Since LMB-100 targets this particular protein, it is less likely to attack healthy … Continue reading Mesothelioma Patients Recruited to Test Promising New Combo Drug
Could Drug “Repurposing” Be the Cure for Mesothelioma?
An exciting new use for an old drug is shining a spotlight on the potential for repurposing previously approved drugs to treat malignant mesothelioma faster and more effectively. Malignant mesothelioma is the cancer most closely associated with the mineral asbestos. Although it’s incidence is slowly declining in some parts of the world, mesothelioma continues to rise in many poor countries where asbestos regulation is lax or nonexistent. While there are some exciting new therapies on the horizon there is still no cure for mesothelioma. But some scientists say using existing drugs to treat the asbestos cancer might be the key to curing it sooner rather than later. Parasite Drug the Latest to Show Promise for Mesothelioma The latest repurposed drug … Continue reading Could Drug “Repurposing” Be the Cure for Mesothelioma?
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!